Janssen Psoriasis

jansen psoriasis

Monash University announced an extension of its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, where researchers will investigate triggers of the immune-mediated disease, psoriasis, and focus on the discovery of potential new treatment approaches to prevent psoriasis.

The collaboration, facilitated by Monash Innovation and Johnson & Johnson Innovation, Asia Pacific, will continue to focus on ground-breaking research to examine the interplay between genetic and environmental triggers of psoriasis, a disease which affects 125 million people worldwide and 300,000 Australians.

The collaboration is an extension of a three-year research program focused on the development of novel approaches to treat autoimmune disease through Monash University’s technological capabilities and world-leading research expertise.  Professor Jamie Rossjohn, from the Biomedicine Discovery Institute, Faculty of Medicine, will lead the research team at Monash University on the three-year research program.

Find out more.